High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease.

[1]  I. W. Mclean,et al.  PERIODATE-LYSINE-PARAFORMALDEHYDE FIXATIVE A NEW FIXATIVE FOR IMMUNOELECTRON MICROSCOPY , 1974, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .

[3]  E. Reinherz,et al.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Janossy,et al.  Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. , 1981, Journal of immunology.

[5]  L. Nadler,et al.  Expression of cell surface markers after human B lymphocyte activation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Nadler,et al.  Stages of B cell differentiation in human lymphoid tissue , 1981, The Journal of experimental medicine.

[7]  N. Bolton,et al.  Nuclear androgen receptors in the epithelium and stroma of human benign prostatic hypertrophic glands , 1983, The Prostate.

[8]  P. Pinkerton,et al.  The natural‐killer‐cell‐associated HNK‐1 (Leu‐7) antibody reacts with hypertrophic and malignant prostatic epithelium , 1985, Cancer.

[9]  George L. Wright,et al.  Antiprostate carcinoma monoclonal antibody (D83.21) cross reacts with a membrane antigen expressed on cytomegalovirus‐transformed human fibroblasts , 1985, The Prostate.

[10]  O. Majdic,et al.  Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes. , 1985, Cellular immunology.

[11]  I. Hilgert,et al.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. , 1989, Molecular immunology.

[12]  Hon Cheung Lee,et al.  Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. , 1989, The Journal of biological chemistry.

[13]  J. Bell,et al.  Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. , 1990, Journal of immunology.

[14]  P. Janssen,et al.  R 75251, a new inhibitor of steroid biosynthesis , 1990, The Prostate.

[15]  G. Kramer,et al.  Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[16]  D. States,et al.  Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38. , 1992, Trends in biochemical sciences.

[17]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[18]  S. Zhao,et al.  Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic acid. , 1993, Biochemical and biophysical research communications.

[19]  A. Jardin,et al.  Benign prostatic hypertrophy. , 1993, European urology.

[20]  J. Bazan,et al.  Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. , 1993, Science.

[21]  F. Malavasi,et al.  Human CD38: a glycoprotein in search of a function. , 1994, Immunology today.

[22]  M. Andreeff,et al.  Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells Is Mediated through Retinoic Acid Receptor-α , 1994 .